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Background: Although the association between multimorbidity and polypharmacy has been clearly documented,
no study has analyzedwhether or not speciﬁc combinations of diseases inﬂuence the prescription of polypharmacy
in older persons.We assessedwhich clusters of diseases are associatedwith polypharmacy in acute-care elderly in-
patients.
Methods: This cross-sectional studywas held in 38 Italian internal medicine and geriatric wards participating in the
Registro Politerapie SIMI (REPOSI) study during 2008. The study sample included 1155 in-patients aged 65 years
or older. Clusters of diseases, deﬁned as two or more co-occurring speciﬁc chronic diseases, were identiﬁed using
the odds ratio (OR) for the associations between pairs of diseases followed by cluster analysis. Polypharmacy was
deﬁned as the prescription of ﬁve or more different medications at hospital discharge. Logistic regression models
were run to analyze the association between clusters of diseases and polypharmacy.
Results: Among clusters of diseases, the highest mean number of drugs (N8) was found in patients affected by
heart failure (HF) plus chronic obstructive pulmonary disease (COPD), HF plus chronic renal failure (CRF), COPD
plus coronary heart disease (CHD), diabetesmellitus plus CRF, and diabetesmellitus plus CHD plus cerebrovascular
disease (CVD). The strongest association between clusters of diseases and polypharmacy was found for diabetes
mellitus plus CHD plus CVD, diabetes plus CHD, and HF plus atrial ﬁbrillation (AF).
Conclusions: The observed knowledge of the relationship among co-occurring diseases and polypharmacy should
help to identify and monitor older in-patients at risk of polypharmacy.
© 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Polypharmacy is very common in older adults andmaywell be need-
ed to improve symptoms, disease-related problems and quality of life
[1–3]. Although polypharmacy has been deﬁned in different ways, we
consider it as the use of ﬁve or more medications regardless of whether
they are necessary or unnecessary. Polypharmacy may also be a major
risk for inappropriate prescribing, poor adherence to therapies, adverse
drug events and other adverse health outcomes [4–7]. Prevalence andessment of Geriatric Therapies
esearch, via Giuseppe La Masa,
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ation of Internal Medicine. Publishepredictors of polypharmacy have been analyzed inmany studies,with re-
sults differing in relation to the clinical setting [3,8,9], but usually the
prevalence of polypharmacy is closely related to the number of diseases
a person has (i.e.multimorbidity) [3,5]. The prevalence ofmultimorbidity
in older persons ranges from35% to80%, dependingon the data collection
method, the deﬁnitions of chronic conditions and multimorbidity, and
the number of chronic conditions included in the analysis [10–15], but
is likely to rise in coming years with the aging of the population [14]. Fur-
thermore, elderly peoplewithmultimorbidity are at high risk of hospital-
ization because of acute events or complications of chronic conditions,
and hospitalization itself is one of the most important risk factors for
polypharmacy [16,17].
Besides multimorbidity, speciﬁc chronic diseases such as hyperten-
sion, coronary heart disease (CHD), heart failure (HF), chronic obstructive
pulmonary disease (COPD), chronic renal failure (CRF) and diabetesmel-
litus are predictors of polypharmacy [13,14,18–20]. However, to ourd by Elsevier B.V. All rights reserved.
Table 1a
ICD-9 codes used to classifying diseases (corresponding diseases are listed in alphabetical
order).
Diagnoses ICD-9 codes
Anemia 280–285
Anxiety 300
Arthritis 715
Atrial ﬁbrillation (AF) 427
Cerebrovascular diseases (CVD) 430–438
Coronary heart disease (CHD) 410–414
Chronic obstructive pulmonary disease (COPD) 490–496
Chronic renal failure (CRF) 585
Dementia 290,331
Diabetes mellitus 250
Dyslipidemia 272
Gastric diseases 530–536
Heart failure (HF) 428
Hypertension 401–405
Intestinal diseases 560–569
Liver cirrhosis 571
Malignancy 140–165, 170–175, 179–208
Prostate hypertrophy 600
Thyroid diseases 240–246
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ic chronic diseases inﬂuences polypharmacy in elderly in-patients. Since
diseases often cluster together beyond what would be expected by
chance [14,15,21], knowledge of how diseases co-occur might help clini-
cians shift from a disease-based perspective to a patient-based perspec-
tive when prescribing drugs.
With this as background, the aim of this study was to assess which
clusters of diseases were associated with polypharmacy at hospital dis-
charge in Italian elderly persons in acute care wards.
2. Material and methods
2.1. Data collection
The study was conducted between January 2008 and December
2008 in 38 hospitals in different regions of Italy, all participating in
the Registro Politerapie SIMI (REPOSI) study, organized in collaboration
by the Italian Society of Internal Medicine (SIMI) and the Mario Negri
Institute for Pharmacological Research. The REPOSI study was designed
to set up a network of internalmedicine and geriatric wards to evaluate
patients with multiple diseases and multiple drugs. Participation in the
network was voluntary, but attention was paid in the choice of the par-
ticipating centers to their homogeneous composition in terms of geo-
graphic distribution, size and unselected admissions from the territory
or the emergency room.
The speciﬁc aims of the REPOSI studywere: to describe the prevalence
of concurrent multiple diseases and treatments in elderly in-patients; to
correlate their clinical characteristics with the type and number of dis-
eases and treatments and to examine the main clinical outcomes at hos-
pital discharge. The study had two phases, the ﬁrst to create the network
of internal medicine and geriatric wards, and the second to set up a reg-
istry of patients included in the study.
All patients 65 years old or older admitted to the wards participating
in the study were consecutively recruited. Participation was voluntary
and all patients signed informed consent. Data collection complied fully
with Italian law on personal data protection. Under the applicable legal
principles on patients' registries, the study did not require ethical com-
mittee approval. At least 40 patients consecutively admitted to each par-
ticipating center during four separate weeks, about three months apart
(in February, June, September, and December 2008) were included in
the study. A standardized web-based Case Report Form was ﬁlled in by
the attending physicians, including socio-demographic factors, clinical
variables, diagnoses and treatments at hospital admission and discharge,
clinical events during hospitalization and outcome. All the data entered
were collected and checked for quality and consistency by a centralmon-
itor of the coordinating center (Mario Negri Institute for Pharmacological
Research, Milan).
During each index week, all wards had to complete the register of all
patients admitted to theward, and indicate thosewhowere consecutive-
ly enrolled in the study. For patients who were excluded, the reason had
to be given. On the basis of these data, during the fourweeks, the recruit-
ment rate for each ward was nearly 40% of patients admitted. Sixty eight
percent of those excludedwere because of age under 65 years. Other rea-
sons for exclusionwere refusal to participate or to sign informed consent
(23%), seriousness of patient's clinical condition or admission in terminal
state (6%), and other reasons (3%). No difference for age and sex (the only
available data) emerged for these patients in comparison to the enrolled
sample.
The initial study sample included 1411 patients; 79 (5.6%) were ex-
cluded because of missing or incomplete data, 25 for missing data on
hospital outcome and 54 for errors in data input and recording of
socio-demographic and clinical characteristics. Thus, 1332 were avail-
able for the overall analyses. Patients who were not discharged to
home (n=111) were excluded. Of these, 6 were terminally ill at hospi-
tal admission and were transferred to end-of-life care structures; 44
were transferred to rehabilitation units or long-term facilities, and 61to other hospital units for acute medical or surgical conditions arising
in hospital. In addition, 66 patients died during the hospital stay leaving
1155 individuals available for the ﬁnal analyses.
2.2. Assessment of diseases
Diseases examined in this study were collected at hospital admis-
sion and conﬁrmed by clinical examination, clinical history and labora-
tory and instrumental data collected by the attending physicians.
Diagnoses were made using standardized criteria. The International
Classiﬁcation of Diseases — Ninth Revision (ICD-9) (WHO) (http://
icd9cm.chrisendres.com/ accessed January 18, 2010) was used for clas-
sifying all the diseases (Table 1a). Only diseases with prevalence of N5%
(n=19) were taken into account.
For thepurposeof this study, clusters of diseaseswere deﬁned as two
or more co-occurring speciﬁc conditions, according to Boyd and col-
leagues [20]. Diseases' clusters were identiﬁed in a previous study held
in the same population using logistic regression models to analyze the
bivariate associations between pairs of diseases and cluster analysis
(Table 1b) [15,21]. TheCharlson Indexwas employed to examine the co-
existence and severity of multiple diseases [22]. Each condition is
assigned a score of 1, 2, 3 or 6 depending on the associated risk of
dying. The scores are summed up and the total predicts mortality [22].
2.3. Drug prescription and polypharmacy
Drugs were recorded according to the Anatomical Therapeutic
Chemical classiﬁcation system (ATC) (WHO) (http://www.whocc.no/
atc_ddd_index/ accessed January 18, 2010.). Although there is still no
consensus or commonly used cut-off for polypharmacy, we set the
cut-off at ﬁve or more different drugs, because this was the median
number of drugs per patient at hospital admission in the enrolled pa-
tients, and because it is one of the most frequently used cut-offs in the
literature on polypharmacy [2,3,23]. Moreover, this cut-off was the
same used in another published study by REPOSI group [24].
When we computed the presence of polypharmacy, pills containing
a ﬁxed association of two active substances were counted as only one
drug.
2.4. Adverse clinical events
Adverse clinical events were deﬁned as any new acute clinical prob-
lem that arose in hospital [25].
Table 1b
Clusters of diseases previously identiﬁed [21] listed in alphabetical order.
Clusters
COPD and CHD
CRF and anemia
Dementia and arthritis
Diabetes and CHD
Diabetes and CRF
Diabetes and CVD
Diabetes and CHD and CVD
Diabetes and dyslipidemia
Gastric and intestinal diseases
HF and AF
HF and COPD
HF and CRF
Hypertension and CVD
Hypertension and diabetes
Hypertension and dyslipidemia
Liver cirrhosis and anemia
Liver cirrhosis and malignancy
Thyroid dysfunction and AF
CHD = Coronary Heart Disease, AF = Atrial Fibrillation, COPD = Chronic Obstructive
Pulmonary Disease, CVD = Cerebrovascular Disease, CRF = Chronic Renal Failure, HF =
Heart Failure.
Table 2
Socio-demographic characteristics of the patients and prevalence of diseases in the
whole sample and according to polypharmacy. Data are given as means or proportions
(95% conﬁdence intervals) adjusted for participating centers.
All
(n=1155)
5+ drugs
(n=774)
b5 drugs
(n=381)
Age, yrs, mean 79.2 (78.4–80.1) 78.9 (77.9–79.8) 79.8 (78.8–80.8)
Women 53.6 (49.4–57.9) 53.5 (48.4–58.6) 53.9 (48.6–59.3)
Education, yrs, mean 6.3 (5.7–6.9) 6.5 (5.9–7.2) 5.9 (5.2–6.6)
Number of drugs, mean 5.9 (5.6–6.3) 7.5 (7.2–7.7) 3.0 (2.9–3.1)
Number of adverse
clinical events, mean
0.6 (0.3–0.8) 0.6 (0.4–0.9) 0.5 (0.2–0.8)
At least one adverse
clinical event
33.2 (25.8–40.7) 35.1 (27.1–43.1) 29.5 (20.5–38.4)
Charlson Index, mean 2.9 (2.7–3.2) 3.3 (3.1–3.6) 2.2 (1.8–2.6)
Hospital stay, days, mean 11.1 (10.2–12.0) 11.5 (10.5–12.5) 10.5 (9.1–11.8)
Hypertension 58.8 (52.8–64.9) 65.2 (59.1–71.2) 46.1 (39.9–53.1)
Diabetes mellitus 24.3 (20.7–27.9) 29.4 (24.9–33.9) 13.9 (10.6–17.3)
CHD 22.9 (18.8–27.0) 29.7 (24.6–34.7) 9.2 (5.9–12.5)
AF 20.0 (16.8–23.3) 24.4 (20.3–28.4) 11.3 (8.3–14.4)
COPD 19.3 (16.2–22.2) 23.1 (19.2–26.9) 11.6 (7.9–15.3)
CVD 20.1 (15.7–24.4) 22.7 (17.6–27.7) 14.7 (10.9–18.5)
Malignancy 14.7 (11.2–18.1) 14.8 (11.2–18.4) 14.5 (9.1–19.9)
Gastric diseases 14.2 (9.4–19.0) 16.1 (10.2–21.9) 10.1 (6.1–14.9)
Dyslipidemia 13.9 (9.9–18.0) 16.8 (12.1–21.5) 8.2 (4.7–11.6)
CRF 11.5 (8.8–14.3) 14.6 (11.3–18.0) 5.3 (3.1–7.4)
Anemia 9.1 (6.6–11.6) 9.3 (6.6–12.1) 8.7 (5.5–11.8)
Thyroid diseases 9.4 (6.9–11.8) 11.5 (8.6–14.5) 5.0 (2.6–7.4)
HF 8.2 (5.4–11.1) 10.8 (7.2–14.4) 3.2 (5.2–5.8)
Anxiety 7.9 (5.7–10.1) 9.1 (6.4–11.7) 5.5 (2.8–8.3)
Prostate hypertrophy 7.8 (5.6–10.1) 8.9 (6.4–11.4) 5.5 (2.5–8.6)
Liver cirrhosis 8.2 (5.3–11.0) 8.5 (5.3–11.8) 7.4 (3.6–11.1)
Dementia 6.9 (4.2–9.7) 6.5 (3.5–9.4) 7.9 (4.3–11.5)
Arthritis 6.9 (4.6–9.3) 7.3 (4.5–10.0) 6.3 (3.1–9.5)
Intestinal diseases 7.5 (5.2–9.7) 8.4 (6.1–10.7) 5.5 (2.6–8.5)
CHD = Coronary Heart Disease, AF = Atrial Fibrillation, COPD = Chronic Obstructive
Pulmonary Disease, CVD = Cerebrovascular Disease, CRF = Chronic Renal Failure, HF =
Heart Failure.
Table 3
Number of patients affected by speciﬁc diseases (N), mean number of drugs (95% con-
ﬁdence intervals, CI) and odds ratios (OR) for polypharmacy according to single dis-
eases. Findings adjusted for age, sex, education, Charlson Index and participating
centers.
Diseases N Mean no. of drugs (95% CI) OR 95% CI
CHD 264 7.5 (6.9–7.9) 4.0 2.7–6.1
HF 95 7.3 (6.5–8.2) 3.6 1.6–8.1
AF 234 6.7 (6.2–7.1) 2.7 1.9–3.7
Dyslipidemia 161 6.7 (6.1–7.3) 2.4 1.6–3.7
Thyroid diseases 108 6.8 (6.2–7.4) 2.4 1.4–4.1
Hypertension 679 6.4 (6.0–6.8) 2.3 1.8–2.9
CRF 135 7.5 (6.9–8.2) 2.1 1.3–3.3
Diabetes mellitus 281 7.4 (6.9–7.8) 1.9 1.4–2.8
COPD 223 7.2 (6.4–7.9) 1.9 1.3–2.9
Prostate hypertrophy 90 6.8 (6.1–7.6) 1.9 0.9–3.6
Intestinal diseases 87 6.4 (5.9–6.9) 1.8 0.9–3.3
Gastric diseases 164 6.7 (6.1–7.2) 1.6 0.9–2.6
Anxiety 91 6.5 (5.6–7.5) 1.6 0.9–2.7
CVD 231 6.4 (5.9–6.9) 1.5 1.1–2.0
Arthritis 80 6.1 (5.3–6.8) 1.2 0.7–2.1
Anemia 107 6.4 (5.7–7.1) 0.9 0.6–1.3
Liver cirrhosis 96 6.2 (5.5–6.8) 0.8 0.4–1.4
Dementia 80 5.3 (4.6–6.0) 0.8 0.5–1.3
Malignancy 170 6.2 (5.5–6.8) 0.6 0.4–0.9
CVD = Cerebrovascular Disease; HF = Heart Failure, AF = Atrial Fibrillation, COPD =
Chronic Obstructive Pulmonary Disease, CRF = Chronic Renal Failure, CHD= Coronary
Heart Disease.
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Several logistic regression models were run to analyze the associa-
tions between each disease and cluster of diseases with polypharmacy.
The adjustment included age (years), sex, education (years of schooling),
the Charlson Index (score) and participating centers. Further adjustment
for length of hospital stay and adverse clinical events in hospital failed to
signiﬁcantly change the results and to improve the model. All statistical
calculations were done with STATA software 9th version (College Sta-
tion, Texas, US).
3. Results
Of the 1155 patients in the analyses, 54% was women. The mean
age of the patients was 79.2 years (95% CI: 78.4–80.1) and the mean
hospital stay was 11 days (95% CI: 10.2–12.0). The most frequent di-
agnoses at admission were: hypertension followed by diabetes melli-
tus, CHD, AF, CVD, and COPD, and their prevalence was signiﬁcantly
higher in patients prescribed with polypharmacy (Table 2). The aver-
age number of drugs prescribed at hospital discharge was 5.9 (95%
CI: 5.6–6.3); 774 (67%) patients were discharged with polypharmacy.
One third had at least one adverse clinical event during the hospital
stay (range 0–9) (Table 2). The most frequent were urinary infection
(12.0%), fever (6.0%), anemia (5.2%), pneumonia (5.0%), electrolyte
disorders (4.5%), atrial ﬁbrillation (4.3%), heart failure (3.0%), and
acute renal failure (2.7%).
The mean number of prescribed drugs was the highest (N7) in pa-
tients with diabetes mellitus, CHD, COPD, CRF and HF, and the lowest
(b6) in patients with dementia (Table 3). In logistic regression models
several diseases emerged as signiﬁcantly associatedwith the prescription
of polypharmacy at hospital discharge. The association was strongest for
cardiovascular diseases: CHD (OR 4.0; 95% CI: 2.7–6.1), HF (OR 3.6; 95%
CI: 1.6–8.1), and AF (OR 2.7; 95% CI: 1.9–3.7). Malignancy, gastric dis-
eases, anemia, anxiety, prostate hypertrophy, liver cirrhosis, dementia,
arthritis and intestinal diseases were not independently associated with
polypharmacy (Table 3).
Finally, Table 4 shows themean number of prescribed drugs accord-
ing to disease clusters and the results of further logistic regression
models testing the association between different disease clusters and
polypharmacy. The mean number of prescribed drugs was the highest
(N8) in patients with HF plus COPD, HF plus CRF, COPD plus CHD, diabe-
tes mellitus plus CRF, and diabetes mellitus plus CHD plus CVD, and thelowest (b6) in patients with dementia plus arthritis. The association be-
tween clusters of diseases and polypharmacywas strongest for diabetes
mellitus plus CHD plus CVD (OR 9.8; 95% CI: 1.3–72.2).
Table 4
Mean number of drugs (95% conﬁdence intervals, CI) and odds ratios (OR) for poly-
pharmacy according to clusters of diseases. Findings adjusted for age, sex, education,
Charlson Index and participating centers.
Clusters of diseases Mean no. of drugs (95% CI) OR 95% CI
Diabetes and CHD and CVD 8.3 (7.1–9.5) 9.8 1.3–72.2
Diabetes and CHD 8.7 (7.9–9.5) 5.8 2.6–13.2
HF and AF 7.6 (6.7–8.5) 5.5 2.0–14.9
Thyroid dysfunction and AF 7.4 (6.7–8.1) 5.0 1.8–14.1
COPD and CHD 8.3 (7.3–9.2) 4.1 1.7–9.9
Hypertension and dyslipidemia 7.1 (6.5–7.7) 3.7 2.0–6.7
HF and COPD 8.7 (7.4–9.9) 3.7 0.8–16.8
Diabetes and CVD 7.4 (6.7–8.0) 3.2 1.5–6.7
Diabetes and dyslipidemia 7.9 (7.2–8.6) 2.8 1.3–6.1
Diabetes and CRF 8.3 (7.4–9.2) 2.7 0.9–7.9
Hypertension and diabetes 7.7 (7.1–8.2) 2.4 1.6–3.5
Hypertension and CVD 6.7 (6.3–7.1) 2.3 1.7–3.0
HF and CRF 8.2 (6.8–9.6) 2.2 0.4–11.5
CRF and anemia 7.9 (6.5–9.3) 1.8 0.7–4.8
Gastric and gastro-intestinal diseases 7.1 (6.0–8.1) 1.8 0.6–5.4
Arthritis and dementia 5.7 (3.8–7.5) 0.9 0.2–4.5
Liver cirrhosis and anemia 6.5 (4.9–8.1) 0.7 0.2–3.0
Liver cirrhosis and malignancy 6.1 (4.9–7.3) 0.6 0.3–1.6
CVD = Cerebrovascular Disease; HF = Heart Failure, AF = Atrial Fibrillation, COPD =
Chronic Obstructive Pulmonary Disease, CRF= Chronic Renal Failure, CHD = Coronary
Heart Disease.
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This study of hospitalized elderly Italian patients examined the asso-
ciation between the co-occurrence of speciﬁc chronic diseases and poly-
pharmacy by a cluster approach [15,21]. Diseases often cluster together
beyond what would be expected by chance, raising the question of a
possible additive or multiplicative effect on different health-related out-
comes. As reported in a previous study on the same population, patients
with different clusters of diseases not only had different mortality rate
and clinical adverse events in hospital, but speciﬁc combinations of dis-
eases had additive effect on these health outcomes [21]. In the present
study, themeannumber of drugs ranged from5.7 for the cluster arthritis
plus dementia to 8.7 for the clusters HF plus COPD and diabetes plus
CHD. Polypharmacy was strongly associated with the clusters of diabe-
tes plus CHD and CVD, diabetes plus CHD, HF plus AF, and thyroid dys-
function plus AF, after adjustment for demographic characteristics, the
Charlson Index and participating centers. The co-occurrence of diseases
had additive effects on the risk of polypharmacy for diabetes with CHD
and CVD, diabetes plus CHD, AF plus HF, CVD plus diabetes, COPD plus
CHD, and thyroid dysfunction plus AF.
Among the main ﬁndings of this study is that diabetes mellitus, one
of the most frequent diseases of the elderly, tends to cluster; in fact it
was found in six clusters. Considered as a single disease, diabeteswas as-
sociatedwith nearly double the risk of polypharmacy, but clusteredwith
other conditions, especially cardiovascular diseases, showed a much
greater increase in theprescription of polypharmacy compared to diabe-
tes alone, even aftermulti-adjustment. Thus, the risk of polypharmacy in
the elderly patients with diabetes mellitus might be explained by the
high probability of co-occurring diseases. In diabetics polypharmacy is
often unavoidable, sincemultiple drug therapy has become the standard
for most of its common comorbidities, and the potential for marked
polypharmacy is likely continue to rise as more therapeutic options be-
come available [19,26].
Besides diabetes, cardiovascular diseases also inﬂuence the cluster-
ing. These were the most common pathologies with an overall preva-
lence ranging from nearly 60% for hypertension to 20% for AF and
CVD. The co-occurrence of HF and AF and HF and COPD increased the
risk of polypharmacy in comparisonwith the single diseases in the clus-
ters. Extensive use of multiple drugs is common in these patients and is
recommended by international guidelines [27,28]. Advances in cardio-
vascular drug treatment have increased life-expectancy. However,polypharmacy is neither always efﬁcacious nor safe, and often leads to
inappropriate drug use, poor compliance, increased morbidity and
costs [18]. In older persons, the risks of polypharmacy and the potential
for inappropriate therapy must be considered and balanced against the
possible beneﬁts of multiple drug therapies. There is no agreement in
the literature about the beneﬁts of treating older patients with multiple
drugs, especially if they are prescribed for primary or secondary preven-
tion. One of the reasons is that old patients and particularly those very
old or affected bymultimorbidity are rarely included in studies on treat-
ments' outcomes. A new approach to reducing the risks andmaximizing
the beneﬁts of polypharmacymight include the identiﬁcation of patient
groups particularly at risk of being prescribed with polypharmacy. The
disease clustering approach, when evaluating older patients, may help
in monitoring these patients. Furthermore, the next step in this ﬁeld
should be the identiﬁcation of the optimal treatment, in term of both
number of medications and most important appropriateness of pre-
scription, for each cluster of diseases, especially for high frequency clus-
ters, or clusters particularly difﬁcult to be treated.
In the present study polypharmacy was not signiﬁcantly associated
with clusters of chronic disease such as liver cirrhosis and anemia,
liver cirrhosis andmalignancy, CRF and anemia, conditionswhich large-
lymark the terminal phases of life. In the last years of life the number of
prescribed drugs can drop compared to younger ages [1,5,9,29]. We
found similar results for dementia alone or clustered with other condi-
tions. One possible explanation might be that patients with dementia
may be undertreated comparedwith non-demented ones [30]. Another
explanation may be that the severity of dementia may have limited the
applicability of the possible therapeutic options for these patients. Un-
fortunately, data on the severity of dementia and other diseases were
not available in this study.
4.1. Strengths and limitations
Themajor strengths of the REPOSI study include themulticenter de-
sign that involved 38 internal medicine and geriatric wards throughout
Italy, resulting in a sample representative of the hospitalized elderly
population; second, patients were enrolled in four different weeks
(one per season) in order to balance the effect of seasons on the acute
diseases leading to hospital admission. However, a few limitations
must also be mentioned. First, the severity of diseases was not taken
into account, in consideration that the evaluation of disease severity is
usually made difﬁcult owing to several classiﬁcation scales or require-
ment of subjective judgments. Another limitation is the lack of informa-
tion on appropriateness of drug prescribed. However, although the
absolute number of drugs cannot be considered a direct indicator of
prescribing appropriateness [2,5,20], there is growing evidence that
polypharmacy is associated with increases in many adverse outcomes,
including adverse drug reactions, drug–drug or drug–disease interac-
tions, falls, hospital admission, and mortality [4,5,7,9,23]. A further
weakness is that problems can arise when using hospital data for re-
search, because hospital records are not designed for this purpose but
rather for patient care, and their diagnostic qualitymay vary depending
on hospitals, physicians and clinical units. Moreover, admissions are
often selective on the basis of local characteristics, associated medical
conditions and admission policies, which can vary from hospital to hos-
pital. Finally, the REPOSI data set was not planned to include a multidi-
mensional geriatric assessment, because it is not general practice in
internal medicine wards in Italy. Thus we have no information on pa-
tients' functional proﬁles.
Learning points
• Although the association between multimorbidity and polypharmacy
has been clearly documented, no study has analyzed whether or not
speciﬁc combinations of diseases inﬂuence the prescription of poly-
pharmacy in older persons.
601A. Nobili et al. / European Journal of Internal Medicine 22 (2011) 597–602• Polypharmacy is strongly associated with the clusters of diabetes plus
CHD and CVD, diabetes plus CHD, HF plus AF, and thyroid dysfunction
plus AF, after adjustment for demographic characteristics, the Charlson
Index and participating centers.
• The co-occurrence of these diseases had additive effects on the risk
of polypharmacy.
• When evaluating older patients, the disease clustering approach
might help clinicians to identify patients particularly at risk of being
prescribed with polypharmacy.
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